[1] Younossi ZM, Koenig AB, Abdelatif D et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology (Baltimore, 2016, 64:73-84.
[2] Allen AM, Therneau TM, Ahmed OT,et al. Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design. J Hepatol, 2022, 77:1237-1245.
[3] Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology, 2023, 77:1797-1835.
[4] Rowe IA, Allen AM. Hepatic steatosis provides the terroir that promotes the development of cardiovascular risk factors and disease. Hepatology, 2023, 77:1843-1845.
[5] Zhou XD, Targher G, Byrne CD,et al. An international multidisciplinary consensus statement on MAFLD and the risk of CVD. Hepatol Int, 2023, 17:773-791.
[6] Kim D, Konyn P, Sandhu KK et al. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. J Hepatol, 2021, 75:1284-1291.
[7] Schonmann Y, Yeshua H, Bentov I, et al. Liver fibrosis marker is an independent predictor of cardiovascular morbidity and mortality in the general population. Dig Liver Dis, 2021, 53:79-85.
[8] Meyersohn NM, Mayrhofer T, Corey KE, et al. Association of Hepatic Steatosis With Major Adverse Cardiovascular Events, Independent of Coronary Artery Disease. Clin Gastroenterol Hepatol, 2021, 19:1480-1488.e1414.
[9] Alexander M, Loomis AK, van der Lei J, et al. Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults. BMJ, 2019, 367:l5367.
[10] Ahmed HS, Wang N, Carr JJ, et al. The association between hepatic steatosis and incident cardiovascular disease, cancer, and all-cause mortality in a US multicohort study. Hepatology, 2023, 77:2063-2072.
[11] Mantovani A, Csermely A, Petracca G, et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol, 2021, 6:903-913.
[12] Haneuse S, VanderWeele TJ, Arterburn D. Using the E-Value to Assess the Potential Effect of Unmeasured Confounding in Observational Studies. Jama, 2019, 321:602-603.
[13] Wormser D, Kaptoge S, Di Angelantonio E, et al. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet, 2011, 377:1085-1095.
[14] Allen AM, Therneau TM, Larson JJ, et al. Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year-community study. Hepatology, 2018, 67:1726-1736.
[15] Eslam M, Sarin SK, Wong VW, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int, 2020, 14:889-919.
[16] Marso SP, Bain SC, Consoli A,et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New Engl J Med, 2016, 375:1834-1844.
[17] 何方平. 我国NAFLD慢病管理实践现状和建议. 实用肝脏病杂志,2023, 26(4):460-462.
[18] 顾荣,芮法娟,倪文婧,等. 非酒精性脂肪性肝病的规范化管理.实用肝脏病杂志, 2023,26(4):457-459. |
